The effect of Sailuotong (SLT) on neurocognitive and cardiovascular function in healthy adults: a randomised, double-blind, placebo controlled crossover pilot trial

BMC Complementary and Alternative Medicine

Research Article

Andrew Pipingas¹  Con Stough¹  Andrew B. Scholey¹  David A. Camfield²  Frances M. de Blasio³  Alan Yeung⁴  Dennis H. Chang⁴  Genevieve Z. Steiner⁵  Jian-Xun Liu⁶ 

[1] Centre for Human Psychopharmacology, Swinburne University of Technology, VIC 3122, Hawthorn, Australia;Centre for Human Psychopharmacology, Swinburne University of Technology, VIC 3122, Hawthorn, Australia;Illawarra Health & Medical Research Institute, University of Wollongong, NSW 2522, Wollongong, Australia;Centre for Psychophysics, Psychophysiology, and Psychopharmacology; Brain & Behaviour Research Institute; and School of Psychology, University of Wollongong, NSW 2522, Wollongong, Australia;National Institute of Complementary Medicine, and School of Science and Health, Western Sydney University, NSW 2751, Penrith, Australia;National Institute of Complementary Medicine, and School of Science and Health, Western Sydney University, NSW 2751, Penrith, Australia;Centre for Psychophysics, Psychophysiology, and Psychopharmacology; Brain & Behaviour Research Institute; and School of Psychology, University of Wollongong, NSW 2522, Wollongong, Australia;Xiyuan Hospital, China Academy of Chinese Medical Sciences, 100091, Beijing, China;

关键词: Sailuotong (SLT);    Chinese Herbal Medicine (CHM);    EEG;    Event-related potentials (ERPs);    P3(00);    Blood pressure;    Heartrate (HR);    Neurocognition;    Age related cognitive decline;   

DOI  :  10.1186/s12906-016-0989-0

 received in 2014-12-20, accepted in 2016-01-07,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundSailuotong (SLT) is a standardised herbal medicine formula consisting of Panax ginseng, Ginkgo biloba, and Crocus sativus, and has been designed to enhance cognitive and cardiovascular function.MethodsUsing a randomised, double-blind, placebo controlled crossover design, this pilot study assessed the effect of treatment for 1 week with SLT and placebo (1 week washout period) on neurocognitive and cardiovascular function in healthy adults. Sixteen adults completed a computerised neuropsychological test battery (Compass), and had their electroencephalographic (EEG) activity and cardiovascular system function assessed. Primary outcome measures were cognitive test scores and oddball task event-related potential (ERP) component amplitudes. Secondary outcome measures were resting EEG spectral band amplitudes, and cardiovascular parameters.ResultsTreatment with SLT, compared to placebo, resulted in small improvements in working memory, a slight increase in auditory target (cf. nontarget) P3a amplitude, and a decrease in auditory N1 target (cf. nontarget) amplitude. There was no effect of SLT on EEG amplitude in delta, theta, alpha, or beta bands in both eyes open and eyes closed resting conditions, or on aortic and peripheral pulse pressure, and resting heartrate.ConclusionsFindings suggest that SLT has the potential to improve working memory performance in healthy adults; a larger sample size is needed to confirm this.Trial registrationAustralia New Zealand Clinical Trials Registry Trial Registration Id: ACTRN12610000947000.

【 授权许可】

CC BY   
© Steiner et al. 2016